Stock Analysis: Myriad Uranium Corp.

President at Singular Research • Nov 1, 2024 at 5:00 AM EDT

Myriad Uranium’s Copper Mountain uranium project started as a speculative deal but quickly became a potentially transformative play.

Image Source: Myriad Uranium Corp.

Myriad Uranium’s (MYRUF) Copper Mountain uranium project started as a speculative deal but quickly became a potentially transformative play.

Myriad Uranium’s Copper Mountain uranium project started as a speculative deal but quickly became a potentially transformative play as Myriad obtained extensive historical data on the project that is expected to be updated in the near future. Coupled with a favorable U3O8 pricing environment, we are bullish on MYRUF – near term and long-term. We initiate with a BUY-Venture rating and a $1.35 price target.

(Read the PDF report in a full screen by clicking here).

More By This Author:

Acme United Corporation - Upgrade To Buy
DeFi Technologies Record Quarter, FY:24 Guidance Raised
CIA: Further Distribution Growth And Earnings Beat, Maintain Buy-Long-Term Rating

Disclosure:

This research report is for our clients’ informational purposes only. This research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. Any opinion expressed in this report is subject to change without notice and may differ or be contrary to opinions expressed by other professionals or business areas of Singular Research or Millennium. We are under no responsibility to update our research.

The views expressed in this research report accurately reflect the responsible analyst’s personal views about the subject securities or issuers. No part of the analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that analyst in the research report.

Millennium and its affiliates, officers, directors, and employees, excluding analysts, will from time to time have long or short positions in, and buy or sell, the securities or derivatives thereof of covered companies referred to in our research reports. Our affiliates, officers, and directors will not execute on any new recommendation or recommendation change until 48 hours after the dissemination of the report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors.